Clay Siegall Efforts to Eliminate Cancer

Clay Siegall is the co-founder of Seattle Genetics. He is currently the CEO and a member of the board of directors of the company. Seattle Genetics is a biotechnology company with its headquarters in Bothell, Washington, United States. The company has been in operation since 1998. Seattle Genetics primary vision is to conduct research and develop various antibodies needed for cancer treatment therapies. With over twenty years’ experience in cancer research and cancer drugs development, Clay Siegall has aided a lot in the success of Seattle Genetics Company. Before co-founding Seattle Genetics, Mr. Siegall previously worked with various institutions like National Cancer Institute and the National Health Institute between 1988 and 1991, and later the Bristol Meyers Squibb Pharmaceutical Research Institute from 1991 to 1997.

Mr. Siegall has enabled the Seattle Genetics company to attain its current leadership position involving the production of Antibody-drug Conjugates (ADCs). In 2011, Mr. Siegall helped the company secure Food and Drugs Administration (FDA) approval for ADCETRIS (brentuximab vedotin), its first ADC product. ADCETRIS is a drug designed to help prevent complications arising as a result of cancer therapies. Since then, ADCETRIS has been in use in more than sixty countries worldwide. Mr. Siegall has also aided in the Seattle Genetics’ revenue raising activities. He has secured billions through both public and private financing.

Several media outlets have featured Clay Siegall. In May 2015, Seaport World Trade Center’s Pegs Boston interviewed Mr. Siegall about the future of Seattle Genetics and the ADECTRIS drug. The interview happened before the release of ADC drug by FDA. Later on, in September 2016, a report by Hackryonm indicated that indeed Seattle Genetics had received a stamp of approval for the ADC drug. Mr. Siegall is a man driven by desire to find the cure for cancer, a disease that consumes thousands of lives annually. His company is frequently advancing in the production of more potent antibodies that aid in attacking cancer cells.


Leave a Reply

Your email address will not be published. Required fields are marked *